Naltalimide
![]() | |
Systematic (IUPAC) name | |
---|---|
2-[(5α,6β)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]-1H-isoindole-1,3(2H)-dione | |
Identifiers | |
CAS Number | 160359-68-2 |
ATC code | None |
PubChem | CID 16066809 |
ChemSpider | 17226389 |
Chemical data | |
Formula | C28H28N2O5 |
Molar mass | 472.532 g/mol |
| |
|
Naltalimide (INN) (code name TRK-130, formerly TAK 363) is a novel, centrally-acting opioid drug which is under development by Takeda and Toray for the treatment of overactive bladder/urinary incontinence.[1][2] It acts as a potent and selective partial agonist of the μ-opioid receptor (Ki = 0.268 nM, EC50 = 2.39 nM, Emax = 66.1%) over the δ-opioid (Ki = 121 nM, EC50 = 26.1 nM, Emax = 71.0%) and κ-opioid receptors (Ki = 8.97 nM, EC50 = 9.51 nM, Emax = 62.6%).[1] Notably, naltalimide somehow appears to lack certain undesirable side effects such as constipation seen with other μ-opioid receptor agonists such as morphine.[1] It enhances bladder storage via suppression of the afferent limb of the micturition reflex pathway.[1]
References
- 1 2 3 4 Fujimura, M.; Izumimoto, N.; Momen, S.; Yoshikawa, S.; Kobayashi, R.; Kanie, S.; Hirakata, M.; Komagata, T.; Okanishi, S.; Hashimoto, T.; Yoshimura, N.; Kawai, K. (2014). "Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder". Journal of Pharmacology and Experimental Therapeutics 350 (3): 543–551. doi:10.1124/jpet.114.214031. ISSN 1521-0103.
- ↑ http://business.highbeam.com/436989/article-1G1-131689504/trk-130-takeda-toray-licensing-agreement
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.